A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Summary

An exploratory study to evaluate the effect of MEDI0382 on energy balance in overweight and obese participants with type 2 diabetes mellitus

Timeline

Start

2018-09-26

Primary completion

2019-12-22

Completion

2019-12-22

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs MEDI0382; p = 0.011; Mean Difference (Net) -2.58 (90% CI -4.15 to -1.00); ANCOVA NCT03596177 ↗

Publications

• Golubic R, Kennet J, Parker V, Robertson D, Luo D, Hansen L, Jermutus L, Ambery P, Ryaboshapkina M, Surakala M, Laker RC, Venables M, Koulman A, Park A, Evans M. Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Diabetes Obes Metab. 2024 Jul;26(7):2634-2644. doi: 10.1111/dom.15579. Epub 2024 Apr 1.

Drugs

Indications